In conclusion, FGF21 analogs must be tested in new clinical trials, as they appear to exhibit great potential for treating signs of Metabolic Syndrome such as high blood insulin, obesity, and especially hypercholesterolemia. This evidence concerns the gene INS and obesity disorder.